Applied Therapeutics, Inc. financial data

Symbol
APLT on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 212% % 50%
Debt-to-equity 95% % -61%
Return On Equity -66% % 89%
Return On Assets -34% % 80%
Operating Margin -9850% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 144,300,674 shares 24%
Common Stock, Shares, Outstanding 144,300,674 shares 24%
Entity Public Float $478,467,415 USD 648%
Common Stock, Value, Issued $35,000 USD 218%
Weighted Average Number of Shares Outstanding, Basic 145,559,604 shares 0.84%
Weighted Average Number of Shares Outstanding, Diluted 145,559,604 shares 0.84%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $999,000 USD 720%
Research and Development Expense $39,056,000 USD -25%
General and Administrative Expense $60,347,000 USD 52%
Operating Income (Loss) $98,404,000 USD -6.6%
Nonoperating Income (Expense) $80,266,000 USD 94%
Net Income (Loss) Attributable to Parent $18,138,000 USD 90%
Earnings Per Share, Basic 0 USD/shares 96%
Earnings Per Share, Diluted 0 USD/shares 73%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $11,945,000 USD -88%
Other Assets, Current $255,000 USD -30%
Assets, Current $31,654,000 USD -70%
Operating Lease, Right-of-Use Asset $2,468,000 USD 26%
Assets $34,374,000 USD -68%
Accounts Payable, Current $4,800,000 USD 69%
Contract with Customer, Liability, Current $212,000 USD 0%
Liabilities, Current $32,902,000 USD -67%
Operating Lease, Liability, Noncurrent $2,033,000 USD 19%
Liabilities $34,935,000 USD -65%
Retained Earnings (Accumulated Deficit) $636,355,000 USD -2.9%
Stockholders' Equity Attributable to Parent $561,000 USD -110%
Liabilities and Equity $34,374,000 USD -68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $28,636,000 USD -51%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 144,300,674 shares 24%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $28,636,000 USD -130%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11,945,000 USD -88%
Deferred Tax Assets, Valuation Allowance $180,769,000 USD 20%
Deferred Tax Assets, Gross $181,639,000 USD 20%
Operating Lease, Liability $2,500,000 USD 27%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $105,624,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid $3,328,000 USD 18%
Operating Lease, Liability, Current $467,000 USD 77%
Lessee, Operating Lease, Liability, to be Paid, Year Two $803,000 USD 44%
Lessee, Operating Lease, Liability, to be Paid, Year One $803,000 USD 47%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $828,000 USD -3.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three $823,000 USD 50%
Deferred Tax Assets, Operating Loss Carryforwards $114,961,000 USD 22%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $702,000 USD 25%
Additional Paid in Capital $635,759,000 USD 1.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $870,000 USD 526%
Share-based Payment Arrangement, Expense $13,935,000 USD 74%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%